HealthManagement, Volume 2 - Issue 2, Winter 2008
The Wall Street Journal has reported that Pfizer have abandoned the development of medicines for heart diseases. In the past Pfizer dominated the cardiovascular drugs sector with Lipitor being named as the worlds best selling drug in 2007. Due to a reorganisation of research they will be leaving drugs such as Lipitor to focus on other programmes including oncology and Alzheimers. They have however confirmed that heart medicine development will continue but only with drugs in late-stage testing.
